Clinical Trial Update: Study to Evaluate the Safety, Tolerability and Efficacy of Cannabidiol (CBD) as a Steroid-sparing Therapy in Chronic Spontaneous Urticaria (CSU) Patients [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating cannabidiol (CBD) as a steroid-sparing therapy for chronic spontaneous urticaria has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spontaneous Urticaria

Drugs mentioned

• Cannabidiol (cannabidiol)

Snippet

Sponsor: Stero Biotechs Ltd. | Conditions: Chronic Spontaneous Urticaria | Phase 2 | Status: COMPLETED